PepGen Inc. (PEPG) Rating Upgraded With 135% Upside on FREEDOM Data

PepGen Inc. (NASDAQ:PEPG) is among the best fast money stocks to buy now. H.C. Wainwright has reaffirmed its ‘Buy’ rating on PepGen Inc. (NASDAQ:PEPG), while increasing the price target to $12.00 from $8.00, implying a surge of nearly 135%. This optimism stems from the company’s 53.7% mean splicing correction at 15 mg/kg report in its FREEDOM single-dose study for DM1 patients, showcasing the highest level disclosed in DM1 patients till now.

The research firm noted that this nearly 54% splicing correction establishes a new standard, pointing to the high chances of repeat dosing delivering significant functional advancements. While expanding the therapeutic window for PepGen Inc. (NASDAQ:PEPG) to a safe and efficacious dose, this could return massively to real health improvements.

Considering the company’s financials, PepGen Inc. (NASDAQ:PEPG) delivered a return of 34.04% in contrast to the market’s average of 13.10%, reflecting an impressive outperformance of nearly 21%.

PepGen Inc. (NASDAQ:PEPG), headquartered in Boston, Massachusetts, is a clinical-stage biotechnology company specializing in oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Incepted in 2018, the company offers PGN-EDO51, PGN-EDODM1, and PGN-EDO53.

While we acknowledge the potential of PEPG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.